SCHEMBL330471

SCHEMBL330471

CCCCCSCC(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKD3 O94806 3/20 0.46
PRKCG P05129 3/20 0.46
PRKCB P05771 3/20 0.46
PRKCA P17252 3/20 0.46
PRKCH P24723 3/20 0.46
PRKCI P41743 3/20 0.46
PRKCE Q02156 3/20 0.46
PRKCQ Q04759 3/20 0.46
PRKCZ Q05513 3/20 0.46
PRKCD Q05655 3/20 0.46
PRKD1 Q15139 3/20 0.46
CES2 O00748 3/20 0.41
THRB P10828 2/20 0.41
GMNN O75496 1/20 0.41
TP53 P04637 1/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41
CYP2C9 P11712 1/20 0.41
BLM P54132 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15271411 0.97 PRKD3 (0.48) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL15271164 0.97 PRKD3 (0.48) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL15270764 0.97 PRKD3 (0.48) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL15270569 0.97 PRKD3 (0.48) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL15270834 0.97 PRKD3 (0.48) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL15271057 0.97 PRKD3 (0.48) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL15271070 0.97 PRKD3 (0.48) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL7477002 0.92
SCHEMBL19726464 0.83
SCHEMBL1704289 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117924548-A Catalyst component for olefin polymerization, preparation method, catalyst system and olefin polymerization method 中国石油化工股份有限公司 2024-04-26 CN disclosed
EP-3831841-A1 NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF S&T Global Inc. (US) 2021-06-09 EP disclosed
US-20180258038-A1 N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2018-09-13 US disclosed
US-10000450-B2 N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2018-06-19 US disclosed
US-20170166524-A1 N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2017-06-15 US disclosed
US-9650456-B2 Process for producing polydienes BRIDGESTONE CORPORATION (JP) 2017-05-16 US disclosed
US-9611214-B2 N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2017-04-04 US disclosed
EP-2825574-B1 PROCESS FOR PRODUCING POLYDIENES BRIDGESTONE CORP (JP) 2016-02-24 EP disclosed
US-20150031845-A1 Process For Producing Polydienes BRIDGESTONE CORPORATION (JP) 2015-01-29 US disclosed
EP-2825574-A1 PROCESS FOR PRODUCING POLYDIENES Bridgestone Corporation (JP) 2015-01-21 EP disclosed
US-20110172299-A1 THERAPEUTIC SUBSTITUTED CYCLOPENTANES ALLERGAN, INC. (US) 2011-07-14 US disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
US-20090215740-A1 THERAPEUTIC SUBSTITUTED BETA-LACTAMS ALLERGAN, INC. (US) 2009-08-27 US disclosed
US-7576112-B2 Therapeutic N-aryl or N-heteroaryl pyrazolidine and pyrazolidinone derivatives ALLERGAN, INC. (US) 2009-08-18 US disclosed
US-20090088406-A1 N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-04-02 US disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172299-A1 THERAPEUTIC SUBSTITUTED CYCLOPENTANES TUBB6, TUBB3, TUBB2A PRKD3 2312/4885PRKCG 2512/4885PRKCB 2322/4885
US-20090088406-A1 N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS SLC6A2, TPH1, SLC6A3 PRKD3 1677/4885PRKCG 3235/4885PRKCB 3275/4885
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB PRKD3 404/4885PRKCG 452/4885PRKCB 58/4885
US-10000450-B2 N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors SLC6A2, TPH1, SLC6A3 PRKD3 1677/4885PRKCG 3235/4885PRKCB 3275/4885
US-20090215740-A1 THERAPEUTIC SUBSTITUTED BETA-LACTAMS TUBB, GANAB, TUBB6 PRKD3 2751/4885PRKCG 2683/4885PRKCB 2081/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 PRKD3 690/4885PRKCG 1834/4885PRKCB 1106/4885
US-20180258038-A1 N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS SLC6A2, TPH1, SLC6A3 PRKD3 1677/4885PRKCG 3235/4885PRKCB 3275/4885
US-20170166524-A1 N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS SLC6A2, TPH1, SLC6A3 PRKD3 1677/4885PRKCG 3235/4885PRKCB 3275/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 PRKD3 690/4885PRKCG 1834/4885PRKCB 1106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.